Updated May 2026 · ClinicalTrials.gov

RECRUITINGPhase 2INTERVENTIONAL

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (NCT05041907) is a Phase 2 interventional studying COVID-19, sponsored by University of Oxford. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against COVID-19 and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 3,800 participants makes this one of the larger COVID-19 trials currently registered. Trials at this scale are typically global, run across many sites, and designed to generate the definitive evidence package for an FDA approval submission or a label expansion.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient understands the procedures and requirements and is willing and able to give willing to sign a consent form for full participation in the study. - Previously healthy adults, male or female, aged 18 to 60 years at time of consent with early symptomatic COVID-19 - SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets) - Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours). - Oxygen saturation ≥96% measured by pulse-oximetry at time of screening. - Able to walk unaided and unimpeded in ADLs - Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits Who Should NOT Join This Trial: The patient may not enter the study if ANY of the following apply: - Taking any concomitant medications or drugs (see appendix 4)† - Presence of any chronic illness/ condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list) - Laboratory abnormalities discovered at screening (see appendix 4) - For females: pregnancy, actively trying to become pregnant, or lactation - Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4) - Currently participating in another COVID-19 therapeutic or vaccine trial - Evidence of pneumonia (although imaging is NOT required) - healthy women on the oral contraceptive pill are eligible to join the study Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study. * Previously healthy adults, male or female, aged 18 to 60 years at time of consent with early symptomatic COVID-19 * SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets) * Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours). * Oxygen saturation ≥96% measured by pulse-oximetry at time of screening. * Able to walk unaided and unimpeded in ADLs * Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits Exclusion Criteria: The patient may not enter the study if ANY of the following apply: * Taking any concomitant medications or drugs (see appendix 4)† * Presence of any chronic illness/ condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list) * Laboratory abnormalities discovered at screening (see appendix 4) * For females: pregnancy, actively trying to become pregnant, or lactation * Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4) * Currently participating in another COVID-19 therapeutic or vaccine trial * Evidence of pneumonia (although imaging is NOT required) * healthy women on the oral contraceptive pill are eligible to join the study

Treatments Being Tested

DRUG

Nirmatrelvir/ritonavir (e.g. PAXLOVID™)

Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7

DRUG

Nitazoxanide

Nitazoxanide 1.5g BD 7/7

DRUG

Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)

Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7

DRUG

Hydroxychloroquine

Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7

OTHER

No treatment

No treatment (except antipyretics- paracetamol)

DRUG

Monoclonal antibodies

Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0

DRUG

Fluoxetine

Fluoxetine 40mg OD for 7/7

DRUG

Molnupiravir

Molnupiravir 800mg BD for 5/7

DRUG

Sotrovimab

Sotrovimab 500mg given once on D0

DRUG

Ensitrelvir

Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7

DRUG

Monoclonal antibodies

Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0

DRUG

Favipiravir

Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7

DRUG

Ivermectin

Ivermectin 600micrograms/kg/day for 7/7.

DRUG

Remdesivir

Remdesivir 200mg D0 and 100mg for a further 4/7.

DRUG

Atilotrelvir/ritonavir

Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7

DRUG

Metformin

Metformin 500mg TDS 5/7

DRUG

Nirmatrelvir/ritonavir

Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7

DRUG

Nirmatrelvir/ritonavir

Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7

DRUG

Nirmatrelvir

Nirmatrelvir 300mg BD for 5/7

Locations (7)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

Universidade Federal de Minas Gerais

Minas Gerais, Brazil

Laos-Oxford-Mahosot Wellcome Trust Research Unit

Vientiane, Laos

Sukraraj Tropical & Infectious Disease Hospital

Kathmandu, Nepal

The Aga Khan University Hospital

Karachi, Pakistan

Vajira hospital

Bangkok, Thailand

Faculty of Tropical Medicine, Mahidol University

Bangkok, Thailand

Bangplee Hospital

Mueang Samut Prakan, Thailand

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT05041907), the sponsor (University of Oxford), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT05041907 clinical trial studying?

Who can participate in NCT05041907?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT05041907?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT05041907. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT05041907. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.